SOURCE: Cardima, Inc.

July 28, 2006 08:00 ET

Cardima Shareholders Approve All Proposals at Annual Meeting

FREMONT, CA -- (MARKET WIRE) -- July 28, 2006 -- At the Annual Stockholders Meeting of Cardima, Inc. (OTCBB: CRDM) held on July 27, 2006, the Company's stockholders elected Gabriel B. Vegh, Phillip Radlick, Ph.D., John R. Cheney, Tony K. Shum, Tina Sim, and Andrew K. Lee to the Company's Board of Directors. In addition, the Company's stockholders approved the following proposals:

--  An increase in the number of authorized shares of common stock
    issuable pursuant to the Company's 1997 Employee Stock Purchase Plan from
    1,750,000 to 2,500,000 shares.
--  Authorizing the Board of Directors, in its discretion, to amend the
    Company's Certificate of Incorporation to effect a one-for-ten reverse
    stock split of the issued and outstanding shares of the Company's common
    stock.
--  The ratification of the selection of Marc Lumer & Company as the
    Company's independent registered public accounting firm.
    
"Our shareholders' support for the Company's proposals is greatly appreciated," said Gabriel Vegh, Cardima Chief Executive Officer. "We remain committed to our priorities of seeking FDA approval of our REVELATION® Tx and pursuing a strategic transaction for our Surgical Ablation System. These shareholder approvals provide us with the flexibility necessary to achieve our priorities."

About Cardima, Inc.

Since our incorporation in November 1992, we have developed, produced and sold a variety of micro-catheters designed for the diagnosis and treatment of the two most common forms of cardiac arrhythmias: atrial fibrillation (AF) and ventricular tachycardia (VT). Since 2001 our efforts have primarily focused on developing differentiated products that diagnose and treat AF, including our REVELATION® Tx micro-catheter for use in the Electrophysiology (EP) market, and our Surgical Ablation System (SAS) for use in the surgical market.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of our pre-market approval application for the REVELATION® Tx; the prospect for any future clinical trials or regulatory activities; the risks associated with the Apix loan facility's restrictive covenants, security interest, fee provisions and other terms and conditions; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2005, the Company's Quarterly Report on Form 10-QSB for the first quarter ended March 31, 2006, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information